Intravenous acyclovir for the treatment of primary genital herpes

L. Corey, Kenneth Fife, J. K. Benedetti, C. A. Winter, A. Fahnlander, J. D. Connor, M. A. Hintz, K. K. Holmes

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Thirty-one patients with first episodes of genital herpes were randomized in a double-blind fashion to intravenous treatment with saline placebo or acyclovir, 5 mg/kg body weight at 8-hour intervals, for 5 days. The median duration of viral shedding from genital lesions after the onset of therapy was significantly shorter for patients given acyclovir (2 days) than for those given placebo (13 days), p < 0.001. Viral shedding from the pharynx, cervix, urethra, and urine were also shorter in acyclovir-treated patients. (p ≤ 0.01 for each comparison). Local and systemic symptoms were shortened by a mean of 5 days and healing of genital lesions by a mean of 12 days in acyclovir-treated patients. (p < 0.01). Complications during treatment, such as extragenital lesions or urinary retention requiring catheterization, developed in four patients given placebo and in none given acyclovir. (p < 0.05). Intravenous acyclovir substantially decreases the symptoms, duration of lesions, and complications of primary genital herpes.

Original languageEnglish
Pages (from-to)914-920
Number of pages7
JournalAnnals of Internal Medicine
Volume98
Issue number6
StatePublished - 1983
Externally publishedYes

Fingerprint

Herpes Genitalis
Acyclovir
Virus Shedding
Placebos
Therapeutics
Urinary Retention
Urethra
Pharynx
Cervix Uteri
Catheterization
Body Weight
Urine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Corey, L., Fife, K., Benedetti, J. K., Winter, C. A., Fahnlander, A., Connor, J. D., ... Holmes, K. K. (1983). Intravenous acyclovir for the treatment of primary genital herpes. Annals of Internal Medicine, 98(6), 914-920.

Intravenous acyclovir for the treatment of primary genital herpes. / Corey, L.; Fife, Kenneth; Benedetti, J. K.; Winter, C. A.; Fahnlander, A.; Connor, J. D.; Hintz, M. A.; Holmes, K. K.

In: Annals of Internal Medicine, Vol. 98, No. 6, 1983, p. 914-920.

Research output: Contribution to journalArticle

Corey, L, Fife, K, Benedetti, JK, Winter, CA, Fahnlander, A, Connor, JD, Hintz, MA & Holmes, KK 1983, 'Intravenous acyclovir for the treatment of primary genital herpes', Annals of Internal Medicine, vol. 98, no. 6, pp. 914-920.
Corey L, Fife K, Benedetti JK, Winter CA, Fahnlander A, Connor JD et al. Intravenous acyclovir for the treatment of primary genital herpes. Annals of Internal Medicine. 1983;98(6):914-920.
Corey, L. ; Fife, Kenneth ; Benedetti, J. K. ; Winter, C. A. ; Fahnlander, A. ; Connor, J. D. ; Hintz, M. A. ; Holmes, K. K. / Intravenous acyclovir for the treatment of primary genital herpes. In: Annals of Internal Medicine. 1983 ; Vol. 98, No. 6. pp. 914-920.
@article{c1698d8553ec476bbafc7a4c3c38539e,
title = "Intravenous acyclovir for the treatment of primary genital herpes",
abstract = "Thirty-one patients with first episodes of genital herpes were randomized in a double-blind fashion to intravenous treatment with saline placebo or acyclovir, 5 mg/kg body weight at 8-hour intervals, for 5 days. The median duration of viral shedding from genital lesions after the onset of therapy was significantly shorter for patients given acyclovir (2 days) than for those given placebo (13 days), p < 0.001. Viral shedding from the pharynx, cervix, urethra, and urine were also shorter in acyclovir-treated patients. (p ≤ 0.01 for each comparison). Local and systemic symptoms were shortened by a mean of 5 days and healing of genital lesions by a mean of 12 days in acyclovir-treated patients. (p < 0.01). Complications during treatment, such as extragenital lesions or urinary retention requiring catheterization, developed in four patients given placebo and in none given acyclovir. (p < 0.05). Intravenous acyclovir substantially decreases the symptoms, duration of lesions, and complications of primary genital herpes.",
author = "L. Corey and Kenneth Fife and Benedetti, {J. K.} and Winter, {C. A.} and A. Fahnlander and Connor, {J. D.} and Hintz, {M. A.} and Holmes, {K. K.}",
year = "1983",
language = "English",
volume = "98",
pages = "914--920",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Intravenous acyclovir for the treatment of primary genital herpes

AU - Corey, L.

AU - Fife, Kenneth

AU - Benedetti, J. K.

AU - Winter, C. A.

AU - Fahnlander, A.

AU - Connor, J. D.

AU - Hintz, M. A.

AU - Holmes, K. K.

PY - 1983

Y1 - 1983

N2 - Thirty-one patients with first episodes of genital herpes were randomized in a double-blind fashion to intravenous treatment with saline placebo or acyclovir, 5 mg/kg body weight at 8-hour intervals, for 5 days. The median duration of viral shedding from genital lesions after the onset of therapy was significantly shorter for patients given acyclovir (2 days) than for those given placebo (13 days), p < 0.001. Viral shedding from the pharynx, cervix, urethra, and urine were also shorter in acyclovir-treated patients. (p ≤ 0.01 for each comparison). Local and systemic symptoms were shortened by a mean of 5 days and healing of genital lesions by a mean of 12 days in acyclovir-treated patients. (p < 0.01). Complications during treatment, such as extragenital lesions or urinary retention requiring catheterization, developed in four patients given placebo and in none given acyclovir. (p < 0.05). Intravenous acyclovir substantially decreases the symptoms, duration of lesions, and complications of primary genital herpes.

AB - Thirty-one patients with first episodes of genital herpes were randomized in a double-blind fashion to intravenous treatment with saline placebo or acyclovir, 5 mg/kg body weight at 8-hour intervals, for 5 days. The median duration of viral shedding from genital lesions after the onset of therapy was significantly shorter for patients given acyclovir (2 days) than for those given placebo (13 days), p < 0.001. Viral shedding from the pharynx, cervix, urethra, and urine were also shorter in acyclovir-treated patients. (p ≤ 0.01 for each comparison). Local and systemic symptoms were shortened by a mean of 5 days and healing of genital lesions by a mean of 12 days in acyclovir-treated patients. (p < 0.01). Complications during treatment, such as extragenital lesions or urinary retention requiring catheterization, developed in four patients given placebo and in none given acyclovir. (p < 0.05). Intravenous acyclovir substantially decreases the symptoms, duration of lesions, and complications of primary genital herpes.

UR - http://www.scopus.com/inward/record.url?scp=0020503345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020503345&partnerID=8YFLogxK

M3 - Article

VL - 98

SP - 914

EP - 920

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -